About
Paradigm Therapeutics is a biopharmaceutical company developing SD-101 (Zorblesia™), a topical therapy targeting wound healing and lesions for all subtypes of Epidermolysis Bullosa (EB), a rare genetic skin disorder.
Explore Paradigm Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.